206 related articles for article (PubMed ID: 31834456)
1. Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia.
El-Gamal RAE; Abdel-Messih IY; Habashy DM; Zaiema SEG; Pessar SA
Ann Hematol; 2020 Jan; 99(1):31-39. PubMed ID: 31834456
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Erythroferrone, Hepcidin, and Iron Overload Status in Iraqi Transfusion-Dependent β-Thalassemia Major Patients.
Smesam HNK; Albuthabhak HAQ; Arjmand S; Al-Hakeim HK; R Siadat SO
Hemoglobin; 2020 Jul; 44(4):272-277. PubMed ID: 32718192
[TBL] [Abstract][Full Text] [Related]
3. The association between growth differentiation factor-15, erythroferrone, and iron status in thalassemic patients.
Youssry I; Samy RM; AbdelMohsen M; Salama NM
Pediatr Res; 2024 Mar; 95(4):1095-1100. PubMed ID: 37464096
[TBL] [Abstract][Full Text] [Related]
4. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
[TBL] [Abstract][Full Text] [Related]
5. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
[TBL] [Abstract][Full Text] [Related]
6. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
Inomata S; Anan A; Yamauchi E; Yamauchi R; Kunimoto H; Takata K; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Irie M; Shakado S; Sohda T; Sakisaka S
Intern Med; 2019 Oct; 58(20):2915-2922. PubMed ID: 31243222
[TBL] [Abstract][Full Text] [Related]
7. Immunoassay for human serum erythroferrone.
Ganz T; Jung G; Naeim A; Ginzburg Y; Pakbaz Z; Walter PB; Kautz L; Nemeth E
Blood; 2017 Sep; 130(10):1243-1246. PubMed ID: 28739636
[TBL] [Abstract][Full Text] [Related]
8. Erythroferrone and hepcidin as mediators between erythropoiesis and iron metabolism during allogeneic hematopoietic stem cell transplant.
Pirotte M; Fillet M; Seidel L; Jaspers A; Baron F; Beguin Y
Am J Hematol; 2021 Oct; 96(10):1275-1286. PubMed ID: 34310730
[TBL] [Abstract][Full Text] [Related]
9. The effect of erythroferrone suppression by transfusion on the erythropoietin-erythroferrone-hepcidin axis in transfusion-dependent thalassaemia: A pre-post cohort study.
Zaman BA; Rasool SO; Abdo JM
Br J Haematol; 2023 May; 201(3):547-551. PubMed ID: 36535905
[TBL] [Abstract][Full Text] [Related]
10. Differentiating iron-loading anemias using a newly developed and analytically validated ELISA for human serum erythroferrone.
Diepeveen L; Roelofs R; Grebenchtchikov N; van Swelm R; Kautz L; Swinkels D
PLoS One; 2021; 16(7):e0254851. PubMed ID: 34283879
[TBL] [Abstract][Full Text] [Related]
11. Relation of hepcidin gene expression in blood mononuclear cells with iron overload severity among β-thalassemia major patients.
Ayatollahi H; Mousavi Nezhad SF; Talebpour A; Badiei Z; Nezami H
Mol Biol Rep; 2020 Dec; 47(12):9353-9359. PubMed ID: 33231816
[TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis and Iron Parameters in Transfusion-dependent and Nontransfusion-dependent Thalassemias.
Ozturk Z; Gumuslu S; Yalcin K; Kupesiz A
J Pediatr Hematol Oncol; 2021 Jul; 43(5):186-192. PubMed ID: 34157011
[TBL] [Abstract][Full Text] [Related]
13. Erythroferrone exacerbates iron overload and ineffective extramedullary erythropoiesis in a mouse model of β-thalassemia.
Olivera J; Zhang V; Nemeth E; Ganz T
Blood Adv; 2023 Jul; 7(14):3339-3349. PubMed ID: 36995275
[TBL] [Abstract][Full Text] [Related]
14. Regulation of iron homeostasis through the erythroferrone-hepcidin axis in sickle cell disease.
Mangaonkar AA; Thawer F; Son J; Ajebo G; Xu H; Barrett NJ; Wells LG; Bowman L; Clair B; Patel N; Bora P; Jung G; Nemeth E; Kutlar A
Br J Haematol; 2020 Jun; 189(6):1204-1209. PubMed ID: 32030737
[TBL] [Abstract][Full Text] [Related]
15. Peripheral expression of hepcidin gene in Egyptian β-thalassemia major.
Aboul-Enein A; El-Beshlawy A; Hamdy M; Shaheen I; El-Saadany Z; Samir A; El-Samie HA
Gene; 2015 Jun; 564(2):206-9. PubMed ID: 25816754
[TBL] [Abstract][Full Text] [Related]
16. Marathon Run-induced Changes in the Erythropoietin-Erythroferrone-Hepcidin Axis are Iron Dependent.
Tomczyk M; Kortas J; Flis D; Kaczorowska-Hac B; Grzybkowska A; Borkowska A; Lewicka E; Dabrowska-Kugacka A; Antosiewicz J
Int J Environ Res Public Health; 2020 Apr; 17(8):. PubMed ID: 32316587
[TBL] [Abstract][Full Text] [Related]
17. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
18. Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.
Srole DN; Ganz T
J Cell Physiol; 2021 Jul; 236(7):4888-4901. PubMed ID: 33372284
[TBL] [Abstract][Full Text] [Related]
19. Identification of erythroferrone as an erythroid regulator of iron metabolism.
Kautz L; Jung G; Valore EV; Rivella S; Nemeth E; Ganz T
Nat Genet; 2014 Jul; 46(7):678-84. PubMed ID: 24880340
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
